CD4 and myeloid sarcoma: The immunopathology of MS is mainly characterized by increasing the number of pro-inflammatory cells, including CD4+ T cells with the Th1 or Th17 phenotypes, monocytes (CD14+/CD16+), macrophages, dendritic cells, and B cells, and a decrease in the level of Th2, CD3+/CD8+ T cytotoxic (Tcyt) cells and regulatory cells, such as Tregs (CD4+/CD25+/FoxP3+) and Bregs (CD19+/CD5+/Cd1d+) [53,54].